Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: Metadata lists "REVVITY, INC." but the filing text identifies the registrant as PerkinElmer, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: January 3, 2010 (53-week fiscal year)
Overview: PerkinElmer is a leading provider of technology, services, and solutions for diagnostics, research, environmental, safety, security, industrial, and laboratory services markets. The company operates through two primary segments: Human Health and Environmental Health. As of the reporting date, the company employed approximately 8,200 people in continuing operations.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Total Sales | $1,812.2 million | $1,960.0 million |
| Operating Income (Continuing Ops) | $147.6 million | $194.4 million |
| Net Income | $85.6 million | $126.4 million |
| Diluted EPS (Net Income) | $0.73 | $1.07 |
| Gross Margin | 43.0% | 42.6% |
| Operating Margin | 8.1% | 9.9% |
| Cash from Operating Activities | $158.3 million | $214.5 million |
| Total Debt (Long-term + Short-term) | $558.3 million | $509.0 million |
| Cash and Cash Equivalents | $179.7 million | $179.1 million |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 8% ($147.8 million) compared to fiscal 2008. This was driven by a 5% decline in the Human Health segment and a 9% decline in the Environmental Health segment. Factors included decreased demand for medical imaging products, order deferrals due to government stimulus delays, and reduced capital spending by testing labs and semiconductor markets.
- Profitability Pressure: Operating income declined 24% ($46.8 million). While gross margins improved by 42 basis points due to product mix and cost containment, operating margins contracted by 177 basis points due to lower demand, restructuring charges ($20.2 million), increased pension expenses, and foreign exchange impacts.
- Segment Performance:
- Human Health: Sales fell 5% to $736.5 million; Operating income remained relatively flat at $79.9 million.
- Environmental Health: Sales fell 9% to $1,075.7 million; Operating income dropped 34% to $98.4 million.
- Restructuring: The company incurred $20.2 million in pre-tax restructuring charges in 2009 (vs. $6.9 million in 2008) to reduce resources in anticipation of the economic downturn and shift resources to higher growth regions.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management believes the company is well-positioned to weather the economic climate due to its strategic focus on Human Health and Environmental Health. They anticipate continued growth in genetic screening and laboratory services markets, which are less sensitive to economic downturns. The company expects to invest in capital expenditures similar to fiscal 2009 levels to introduce new products and improve processes.
Key Risks & Contingencies:
- Economic Conditions: Continued global economic contraction, credit market tightening, and reduced government funding could further reduce demand.
- Legal Proceedings: Ongoing litigation with Enzo Biochem regarding patent infringement and distributorship agreements; however, management believes resolution will not have a material adverse effect.
- Discontinued Operations: The company ceased plans to sell the Photonics business but remains committed to selling the Photoflash business. Losses on disposition of discontinued operations totaled $2.1 million in 2009.
- Intangible Assets: The company holds $1.9 billion in net intangible assets. Adverse business changes could trigger impairment charges.
Investor Verification Checklist
- Revenue Drivers: Verify the recovery trajectory of the medical imaging and semiconductor markets, which were primary drivers of the sales decline.
- Restructuring Execution: Monitor the realization of cost savings from the $20.2 million restructuring plan to ensure they offset revenue declines as projected.
- Acquisition Integration: Assess the performance of recent acquisitions (Sym-Bio, Analytica, Opto Technology) and the pending ICPMS joint venture purchase ($35 million).
- Debt Covenants: Confirm continued compliance with debt covenants, specifically debt-to-capital ratios, given the increased debt load ($558 million) and economic volatility.
- Discontinued Operations: Track the progress of the Photoflash business divestiture and the final settlement of the Boston facility decommissioning ($1.7 million remaining accrual).